Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.

Journal Article (Journal Article;Review)

Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.

Full Text

Duke Authors

Cited Authors

  • Sheikhbahaei, S; Marcus, C; Hafezi-Nejad, N; Taghipour, M; Subramaniam, RM

Published Date

  • July 2015

Published In

Volume / Issue

  • 10 / 3

Start / End Page

  • 375 - 393

PubMed ID

  • 26099673

Electronic International Standard Serial Number (EISSN)

  • 1879-9809

Digital Object Identifier (DOI)

  • 10.1016/j.cpet.2015.03.003


  • eng

Conference Location

  • United States